Highest-materiality recent filing
Arteris Q1 revenue $22.9M (+39% YoY); CFO Nick Hawkins to retire Aug 31
Revenue $22.9M (+39% YoY); ACV plus royalties $92.8M (+39% YoY).
Arteris Q4 2025 revenue $20.1M (+30% YoY); ACV+royalties record $83.6M
Q4 revenue $20.1M (+30% YoY); full-year revenue $70.6M (+22% YoY).
Arteris agrees to acquire Cycuity for up to $45M in cash and stock
Total consideration up to $45M: $13.5M cash + $19.5M stock at closing, plus up to $12M earnout based on 2026 bookings milestones.
Arteris Q3 revenue $17.4M (+18% YoY); ACV+royalties $74.9M (+24%); RPO tops $100M
Revenue $17.4M (+18% YoY); GAAP operating loss $8.7M vs $7.9M YoY.
Arteris Q2 revenue up 13% YoY to $16.5M; record ACV+royalties $69.1M
Revenue $16.5M (+13% YoY); ACV+royalties $69.1M (record, +15% YoY).
Arteris Q1 revenue $16.5M (+28% YoY); ACV+royalties record $66.8M; free cash flow positive $2.7M
Revenue $16.5M, up 28% YoY; ACV+royalties $66.8M (record, +15% YoY).
Arteris Q4 revenue $15.5M (+24% YoY); ACV+royalties record $65.1M
Full-year 2024 revenue $57.7M (+8% YoY); net loss $33.6M ($0.86/share).
Revenue of $14.7 million; ACV plus royalties hit a record $60.5M, up 6% YoY.
Arteris Q2 2024: revenue $14.6M (+13% seq), record ACV $60.1M, net loss $0.22/share
Revenue $14.6M, up 13% sequentially; ACV+TTM variable royalties $60.1M (+3% YoY); RPO $77.5M (+19% YoY).
Arteris Q1 revenue $12.9M, ACV up 6% to $58.2M, net loss $9.4M; positive free cash flow
Revenue $12.9M; ACV+TTM royalties $58.2M (+6% YoY); RPO $74.7M (+30% YoY).
Arteris reports Q4 revenue $12.5M (+12% YoY); ACV hits $56.1M above guidance
Q4 revenue $12.5M (+12% YoY); FY revenue $53.7M (+7% YoY).
Arteris Q3 revenue $13.3M (+5% YoY); ACV+royalties $57.3M (+8%); guides Q4 rev $11.3-12.3M
ACV+TTM royalties $57.3M, up 8% YoY; net loss $8.2M ($0.23/share); non-GAAP net loss $4.2M ($0.12/share).
Arteris Q2 revenue $14.7M beats guidance; ACV+TTM royalties +13% YoY; Q3 rev guide $12.5-13.5M
Revenue $14.7M exceeded guidance; ACV+TTM royalties $58.2M (+13% YoY, +21% ex-DJI).
Arteris Q1 revenue $13.2M (+12% YoY); net loss $0.26/share; guides FY rev $56-60M
Revenue $13.2M (+12% YoY); ACV+TTM royalties $54.8M (+4% YoY).
Arteris reports FY2022 revenue up 33% to $50.4M; net loss $27.4M; guides FY2023 revenue $56-60M
FY2022 revenue $50.4M (+33% YoY); net loss $27.4M ($0.84/share); non-GAAP net loss $14.7M ($0.45/share).
Arteris Q3 revenue $12.6M up 41% YoY; ACV+TTM royalties $53.2M up 17%
Revenue $12.6M (up 41% YoY); ACV+TTM royalties $53.2M (up 17% YoY).
Arteris Q2 revenue $14.8M (+37% YoY); ACV+royalties $51.7M, guides Q3 rev $10.5-12.5M
Revenue $14.8M up 37% YoY; ACV + TTM royalties $51.7M up 18% YoY.
Arteris Q1 revenue $11.8M (+77% YoY); ACV+TTM royalties $52.8M (+26%); guides Q2 rev $11.5-14.5M
Revenue $11.8M (+77% YoY); GAAP net loss $6.8M ($0.22/share); non-GAAP net loss $4.4M ($0.14/share).
Arteris Q4 revenue $11.4M, FY21 revenue $37.9M (+19% YoY); guides FY22 rev $47-51M
Q4 2021 revenue $11.4M; full-year 2021 revenue $37.9M, up 19% YoY.
AHK will contribute RMB 77.33M via technology license and RMB 1.7M cash, plus transfer of initial capital, for 40.321% of Transchip.
Arteris Q3 revenue up 39% YoY to $9.0M; guides Q4 $10-11.1M
Revenue $9.0M (+39% YoY); net loss $5.0M ($0.24 per share); non-GAAP net loss $4.4M ($0.21).
Arteris completes IPO of 5.75M shares at $14.00; gross proceeds $80.5M
Completed IPO of 5,750,000 shares at $14.00 per share, including full exercise of underwriters' option.
Nick Hawkins, Chief Financial Officer of the Company, notified the Company he will retire effective August 31, 2026.
On March 25, 2025, Isabelle F. Geday notified the board of directors (the “Board”) of Arteris, Inc. (the “Company”) of her decision to resign from the Board, effective as of March 27, 2025.
On September 13, 2024, the Board of Directors (the “Board”) of Arteris, Inc. (the “Company”) upon the recommendation of the Nominating and Corporate Governance Committee (“NCG Committee”), approved Joachim Kunkel to be appointed to the Board effective September 16, 2024.
appointed Claudia Fan Munce to the Board to fill the vacancy resulting from the increase in the number of authorized directors, with Ms. Munce being appointed to the Board effective May 1, 2022.
Christian Claussen delivered notice of his intention to not stand for reelection to the Board at the Company’s upcoming annual meeting of shareholders
effective as of December 1, 2021, Isabelle Geday, a member of the Board and a named executive officer, transitioned to a consulting role with the Company and entered into a consulting agreement with the Company.
Max materiality 1.00 · Median 0.65 · Most common event earnings